![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Hepatitis C Virus Treatment Response to Ledipasvir/Sofosbuvir among patients co-infected with HIV and HCV: Real World Data in a Black Population
 
|
|
|
Reported by Jules Levin
IDWeek2017/IDSA, October 4-8, 2017, San Diego  
Banga J MD, MPH1, Nizami S MD1, Portilla M RN1, Slim J MD2, Nagarakanti S MD3, Swaminathan S MD1
1. Rutgers New Jersey Medical School, Newark, NJ; 2. Saint Michael's Medical Center, Newark, NJ, 3.Beth Israel Medical Center, Newark, NJ
![1011171](../images/101117/101117-5/1011171.gif)
![1011172](../images/101117/101117-5/1011172.gif)
![1011173](../images/101117/101117-5/1011173.gif)
References  
1. Lo Re V, Kallan MJ, Tate JP, et al. Hepatic decompensation in antiretroviral-treated patients coinfected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. Ann Intern Med. 2014;160(6):369-379  
2. Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology. 2008b;48(2):418-431.  
3. de Ledinghen V, Barreiro P, Foucher J, et al. Liver fibrosis on account of chronic hepatitis C is more severe in HIV-positive than HIV-negative patients despite antiretroviral therapy. J Viral Hepat. 2008;15(6):427-433.  
4. Fierer DS, Dieterich DT, Fiel MI, et al. Rapid progression to decompensated cirrhosis, liver transplant, and death in HIV-infected men after primary hepatitis C virus infection. Clin Infect Dis. 2013;56(7):1038-1043.  
5. Kirk GD, Mehta SH, Astemborski J, et al. HIV, age, and the severity of hepatitis C virus-related liver disease: a cohort study. Ann Intern Med. 2013;158(9):658-666.  
6. Naggie S, Cooper C, Saag M, et al. Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med. 2015
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|